Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
Source: BioPharma Dive - Latest News
The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.